{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:14:08Z","timestamp":1787030048348,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in December 2019, causing millions of deaths all over the world, and the lack of specific treatment for severe forms of coronavirus disease 2019 (COVID-19) have led to the development of vaccines in record time, increasing the risk of vaccine safety issues. Recently, several cases of thrombotic thrombocytopenic purpura (TTP) have been reported following COVID-19 vaccination. TTP is a rare disease characterized by thrombocytopenia, microangiopathic hemolytic anemia and ischemic end-organ lesions. It can be either congenital or acquired. Various events such as viral infections, medication, pregnancy, malignancies, and vaccinations may cause TTP. Here, we report two cases of acquired TTP following Sinopharm COVID-19 vaccine (BBIBP-CorV) and Sinovac COVID-19 vaccine (CoronaVac). Diagnosis was based on clinical presentation and confirmed with a severe reduction in the activity of von Willebrand factor-cleaving protease ADAMTS-13 and the presence of inhibitory autoantibodies. The two patients were successfully treated with corticosteroids, plasma exchange therapy and rituximab in the acute phase. In the literature, the reported cases of TTP induced by COVID-19 vaccination occurred after Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based COVID-19 vaccines. To the best of our knowledge, this is the first report of acquired TTP after inactivated virus COVID-19 vaccination.<\/jats:p>","DOI":"10.3390\/vaccines10071012","type":"journal-article","created":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T22:50:23Z","timestamp":1656283823000},"page":"1012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8698-9339","authenticated-orcid":false,"given":"Imen","family":"Ben Saida","sequence":"first","affiliation":[{"name":"Medical Intensive Care Unit, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"},{"name":"Research Laboratory Heart Failure, LR12SP09, Farhat Hached University Hospital, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iyed","family":"Maatouk","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0775-8562","authenticated-orcid":false,"given":"Radhouane","family":"Toumi","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"},{"name":"Research Laboratory Heart Failure, LR12SP09, Farhat Hached University Hospital, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-3280","authenticated-orcid":false,"given":"Emna","family":"Bouslama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Ben Ismail","sequence":"additional","affiliation":[{"name":"Department of Hematology, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaker","family":"Ben Salem","sequence":"additional","affiliation":[{"name":"Department of Pharmacovigilance, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7557-2156","authenticated-orcid":false,"given":"Mohamed","family":"Boussarsar","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Faculty of Medicine of Sousse, University of Sousse, Sousse 4000, Tunisia"},{"name":"Research Laboratory Heart Failure, LR12SP09, Farhat Hached University Hospital, University of Sousse, Sousse 4000, Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jama.2020.5394","article-title":"Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy","volume":"323","author":"Grasselli","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Saida, I.B., Ennouri, E., Nachi, R., Meddeb, K., Mahmoud, J., Thabet, N., Jerbi, S., and Boussarsar, M. (2020). Very Severe COVID-19 in the Critically Ill in Tunisia. Pan Afr. Med. J., 35.","DOI":"10.11604\/pamj.supp.2020.35.2.24753"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/17476348.2021.1854092","article-title":"An Effective Drug against COVID-19: Reality or Dream?","volume":"15","author":"Yaghoubi","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/21645515.2020.1820808","article-title":"Recombinant Vaccines for COVID-19","volume":"16","author":"Yadav","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/14760584.2021.1949293","article-title":"COVID-19 Vaccines: Concerns beyond Protective Efficacy and Safety","volume":"20","author":"Lai","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1002\/jmv.27214","article-title":"Safety of COVID-19 Vaccines","volume":"93","author":"Alkhaffaf","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and Safety of the CoronaVac Inactivated Vaccine in Patients with Autoimmune Rheumatic Diseases: A Phase 4 Trial","volume":"27","author":"Aikawa","year":"2021","journal-title":"Nat. Med."},{"key":"ref_8","first-page":"e2140364","article-title":"Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1111\/bcp.14763","article-title":"Postvaccination Anaphylaxis and MRNA-Based SARS-CoV-2 Vaccines\u2014Much Ado about Nothing?","volume":"87","author":"Marcec","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"J\u0119\u015bkowiak, I., Wiatrak, B., Grosman-Dziewiszek, P., and Szel\u0105g, A. (2021). The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines, 9.","DOI":"10.3390\/vaccines9050502"},{"key":"ref_11","first-page":"4130138","article-title":"Recurrence of Thrombotic Thrombocytopenic Purpura after MRNA-1273 COVID-19 Vaccine Administered Shortly after COVID-19","volume":"2021","author":"Karabulut","year":"2021","journal-title":"Case Rep. Hematol."},{"key":"ref_12","first-page":"207","article-title":"Acquired Thrombotic Thrombocytopenic Purpura Following Pfizer COVID-19 Vaccination","volume":"3","author":"Alislambouli","year":"2022","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2169\/internalmedicine.8568-21","article-title":"Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 MRNA Coronavirus Disease Vaccination in a Japanese Patient","volume":"61","author":"Yoshida","year":"2022","journal-title":"Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2021.279535","article-title":"Immune-Mediated Thrombotic Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine","volume":"107","author":"Giuffrida","year":"2021","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the Diagnosis and Management of Thrombotic Thrombocytopenic Purpura and Other Thrombotic Microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and Adults with Thrombotic Thrombocytopenic Purpura Associated with Severe, Acquired Adamts13 Deficiency: Comparison of Incidence, Demographic and Clinical Features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1164\/rccm.2107138","article-title":"The Richmond Agitation-Sedation Scale: Validity and Reliability in Adult Intensive Care Unit Patients","volume":"166","author":"Sessler","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_18","first-page":"21","article-title":"Hyaline Thrombosis of the Terminal Arterioles and Capillaries: A Hitherto Undescribed Disease","volume":"24","author":"MOSCHCOWITZ","year":"1924","journal-title":"Proc. N. Y. Pathol. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12254-018-0429-6","article-title":"Thrombotic Thrombocytopenic Purpura","volume":"11","year":"2018","journal-title":"Memo"},{"key":"ref_20","first-page":"e16619","article-title":"Thrombotic Thrombocytopenic Purpura Presentation in an Elderly Gentleman Following COVID Vaccine Circumstances","volume":"13","author":"Chamarti","year":"2021","journal-title":"Cureus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jha2.219","article-title":"Acquired Thrombotic Thrombocytopenic Purpura with Possible Association with AstraZeneca-Oxford COVID-19 Vaccine","volume":"2","author":"Shalaby","year":"2021","journal-title":"EJHaem"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-021-03190-y","article-title":"Thrombotic Thrombocytopenic Purpura: A New Menace after COVID Bnt162b2 Vaccine","volume":"114","author":"Waqar","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and External Validation of the PLASMIC Score for Rapid Assessment of Adults with Thrombotic Microangiopathies: A Cohort Study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External Validation of the PLASMIC Score: A Clinical Prediction Tool for Thrombotic Thrombocytopenic Purpura Diagnosis and Treatment","volume":"16","author":"Li","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/jth.15418","article-title":"First Report of a de Novo ITTP Episode Associated with an MRNA-based Anti-COVID-19 Vaccination","volume":"19","author":"Maes","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2021.12.029","article-title":"Immune Thrombotic Thrombocytopenic Purpura Following Pfizer-BioNTech Anti-COVID-19 Vaccination in a Patient Healed from Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"210","author":"Innao","year":"2022","journal-title":"Thromb. Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Olivieri, B., Betterle, C., and Zanoni, G. (2021). Vaccinations and Autoimmune Diseases. Vaccines, 9.","DOI":"10.3390\/vaccines9080815"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e246049","DOI":"10.1136\/bcr-2021-246049","article-title":"Thrombotic Thrombocytopenic Purpura after ChAdOx1 NCoV-19 Vaccine","volume":"14","author":"Lee","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/jth.15420","article-title":"Acquired Thrombotic Thrombocytopenic Purpura: A Rare Disease Associated with BNT162b2 Vaccine","volume":"19","author":"Maayan","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1055\/s-0041-1732342","article-title":"Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 MRNA Vaccine","volume":"5","author":"Pavenski","year":"2021","journal-title":"TH Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-Induced Immune Thrombotic Thrombocytopenia","volume":"9","author":"Klok","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_32","unstructured":"Aleem, A., and Nadeem, A.J. (2022). Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). StatPearls, StatPearls Publishing."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tews, H.C., Driendl, S.M., Kandulski, M., Buechler, C., Heiss, P., St\u00f6ckert, P., Heissner, K., Paulus, M.G., Kunst, C., and M\u00fcller, M. (2022). SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia with Venous Thrombosis, Pulmonary Embolism, and Adrenal Haemorrhage: A Case Report with Literature Review. Vaccines, 10.","DOI":"10.3390\/vaccines10040595"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of Thrombotic Thrombocytopenic Purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int. J. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Osmanodja, B., Schreiber, A., Schrezenmeier, E., and Seelow, E. (2021). First Diagnosis of Thrombotic Thrombocytopenic Purpura after SARS-CoV-2 Vaccine\u2014Case Report. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02616-3"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103145","DOI":"10.1016\/j.transci.2021.103145","article-title":"Relapse of Thrombotic Thrombocytopenic Purpura after COVID-19 Vaccine","volume":"60","author":"Sissa","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"441.e3","DOI":"10.1016\/j.ajem.2021.05.001","article-title":"Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination","volume":"49","author":"Yocum","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e12658","DOI":"10.1002\/rth2.12658","article-title":"Clinical Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura Following COVID-19 Vaccination","volume":"6","author":"Deucher","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/bjh.17782","article-title":"Thrombotic Thrombocytopenic Purpura Temporally Associated with BNT162b2 Vaccination in an Adolescent Successfully Treated with Caplacizumab","volume":"196","author":"Kirpalani","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00277-021-04584-y","article-title":"Acquired Thrombotic Thrombocytopenic Purpura after First Vaccination Dose of BNT162b2 MRNA COVID-19 Vaccine","volume":"101","author":"Ruhe","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.2021015149","article-title":"Immune-Mediated Thrombotic Thrombocytopenic Purpura Following COVID-19 Vaccination","volume":"139","author":"Picod","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2040620720902904","DOI":"10.1177\/2040620720902904","article-title":"Caplacizumab in Adult Patients with Acquired Thrombotic Thrombocytopenic Purpura","volume":"11","author":"Hanlon","year":"2020","journal-title":"Ther. Adv. Hematol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:39:09Z","timestamp":1760139549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/7\/1012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["vaccines10071012"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10071012","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]}}}